Sign In
Buy JNJ
$231.29
+2.90 (+1.27%)
At Close: Jun 22, 2026
Want $1,400 in Passive Income? Invest $10,000 Into These 4 Dividend Stocks
08:30am, Friday, 29'th May 2026
Passive income arrives on its own schedule, no effort required. Dividends keep landing in the brokerage account on a predictable schedule, regardless of headlines or market moves.
Building on the recent approval of Johnson & Johnson's TECVAYLI ® plus DARZALEX FASPRO® , MajesTEC-9 is the second positive Phase 3 study to reinforce the strength of TECVAYLI ® as early as second
VYM vs. SCHD: Which U.S. Dividend ETF Is a Better Buy?
06:00am, Friday, 29'th May 2026
When choosing dividend ETFs, diversification is a top priority.
FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
07:10pm, Thursday, 28'th May 2026
TREMFYA ® showed significant inhibition of structural joint damage in adults with active psoriatic arthritis HORSHAM, Pa., May 28, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today t
Is Johnson & Johnson (JNJ) a Buy as Wall Street Analysts Look Optimistic?
10:31am, Thursday, 28'th May 2026
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe
J&J Stock Gains Nearly 12% Year to Date: Buy, Sell or Hold Now?
09:25am, Thursday, 28'th May 2026
JNJ is up nearly 12% YTD as strong oncology drug growth, MedTech demand and pipeline advances help offset Stelara patent-loss pressure.
VHT vs. XBI: Vanguard Health Care ETF Tops SPDR Biotech in Yield and Cost
08:07am, Thursday, 28'th May 2026
Expense ratios, yield, and sector breadth set these healthcare ETFs apart-see how their risk profiles and portfolio strategies compare.
J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?
05:30am, Thursday, 28'th May 2026
Partnership strategy has produced great pharma bargains—and left the company exposed.
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
04:22pm, Wednesday, 27'th May 2026
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 15th to review second-quarter results. Joaq
Johnson & Johnson (JNJ) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
02:27pm, Wednesday, 27'th May 2026
Johnson & Johnson (JNJ) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
GLP-1 Drugs Powered IHE's Big Year. IXJ Is Playing a Longer Game.
11:17am, Wednesday, 27'th May 2026
A closer look at portfolio makeup, yield, and risk reveals what sets these two iShares healthcare funds apart for investors seeking sector exposure.
President Trump's Drug Pricing Policies Could Hurt Drugmakers' Profits. Time to Sell Pharma Stocks?
03:25pm, Tuesday, 26'th May 2026
Don't be too quick to give up on the industry.
4 Large-Cap Pharma Stocks to Buy as Industry Recovery Accelerates
09:51am, Tuesday, 26'th May 2026
In the Large-Cap Pharmaceuticals industry, LLY, J&J, NVO and BAYRY are worth retaining as the industry shows some recovery.
Inflation Adjusted Dividend Income: How to Replace $80,000 in Today’s Dollars 20 Years From Now
09:32am, Tuesday, 26'th May 2026
A 50-year-old woman planning to retire at 70 on the equivalent of $80,000 in today's purchasing power is actually targeting a much larger nominal income figure. Assuming long-run inflation averages 3%
How $450,000 Can Deliver a $27,000 Paycheck Without Working a Day
07:30am, Tuesday, 26'th May 2026
A $450,000 portfolio generating a 6% blended yield produces about $27,000 per year in income. For many early retirees between ages 55 and 65, that can function as a financial bridge between leaving fu
